Printer Friendly

Lexicon extends intellectual property portfolio with patent on gene trapping.

Lexicon Genetics, Inc. (The Woodlands, TX) announced the issuance of United States Patent 6,776,988 (the "988 patent") entitled "Vectors for gene mutagenesis and gene discovery." The 988 patent is Lexicon's seventh related to its proprietary gene trapping technology.

The 988 patent covers cells that have been genetically engineered using Lexicon's third-generation gene trapping constructs. The newly-issued patent covers the substantial majority of the more than 270,000 embryonic stem cell clones present in Lexicon's OmniBank library and identified by DNA sequence in Lexicon's OmniBank database. The patent also covers the cells of knockout mice and other model organisms containing genetic modifications that were made using the technology.

Lexicon scientists use gene knockout technology -- both gene trapping and gene targeting -- to systematically discover the physiological functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon has a pipeline of more than 40 drug discovery programs that resulted from discoveries made using these patented technologies.

Lexicon is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The company has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, cancer, immune system disorders, ophthalmic disease, and psychiatric and neurological disorders. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries.

Lexicon Genetics, Inc.

+1-281-863-3503

www.lexicon-genetics.com
COPYRIGHT 2004 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Lexicon extends intellectual property portfolio with patent on gene trapping.
Publication:BIOTECH Patent News
Geographic Code:1USA
Date:Aug 1, 2004
Words:278
Previous Article:Pharming acquires patent portfolio of PPL therapeutics.
Next Article:Corgentech announces patent issuance for E2F transcription factor decoy technology.
Topics:


Related Articles
Lexicon Genetics announces issuance of two key gene trapping patents.
Transkaryotic awarded patent relating to production and delivery of proteins.
Targeted Genetics obtains gene expression patent.
Key patent obtained for Introgen's Phase 3 product.
Lexicon patents gene trapping technology.
Lexicon Genetics broadens patent portfolio with knockout mouse patent.
Aegera adds six patents to their apoptosis patent estate.
Advanced Cell expands somatic cell nuclear transfer cellular reprogramming intellectual property portfolio.
Lexicon granted exclusive license to Cellectis' homologous recombination technology.
Ryogen licenses human aminopeptidase P gene patent to OriGene.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters